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Abstract
Background: Multimorbidity is associated with higher healthcare resource utilization, but we lack data on the
association of specific combinations of comorbidities with healthcare resource utilization. We aimed to identify the
combinations of comorbidities associated with high healthcare resource utilization among multimorbid medical
inpatients.
Methods: We performed a multicentre retrospective cohort study including 33,871 multimorbid (≥2 chronic
diseases) medical inpatients discharged from three Swiss hospitals in 2010–2011. Healthcare resource utilization was
measured as 30-day potentially avoidable readmission (PAR), prolonged length of stay (LOS) and difference in
median LOS. We identified the combinations of chronic comorbidities associated with the highest healthcare
resource utilization and quantified this association using regression techniques.
Results: Three-fourths of the combinations with the strongest association with PAR included chronic kidney
disease. Acute and unspecified renal failure combined with solid malignancy was most strongly associated with
PAR (OR 2.64, 95%CI 1.79;3.90). Miscellaneous mental health disorders combined with mood disorders was the most
strongly associated with LOS (difference in median LOS: 17 days) and prolonged LOS (OR 10.77, 95%CI 8.38;13.84).
The number of chronic diseases was strongly associated with prolonged LOS (OR 9.07, 95%CI 8.04;10.24 for ≥10
chronic diseases), and to a lesser extent with PAR (OR 2.16, 95%CI 1.75;2.65 for ≥10 chronic diseases).
Conclusions: Multimorbidity appears to have a higher impact on LOS than on PAR. Combinations of comorbidities
most strongly associated with healthcare utilization included kidney disorders for PAR, and mental health disorders
for LOS.
Keywords: Multimorbidity, Comorbidity, Chronic diseases, Combinations, Readmission, Potentially avoidable
readmission, Length of stay, Healthcare utilization
Background
With the progress of medical science, survival has in-
creased for patients with several chronic diseases, lead-
ing to a higher prevalence of multimorbidity, most often
defined as the presence of at least two chronic diseases
[1–3]. Given its association with poor quality of life,
functional decline and healthcare resource utilization,
multimorbidity represents a significant burden for the
healthcare systems and the patients [4–6].
Potentially avoidable readmission (PAR) and length of
stay (LOS) are two different and relatively simple mea-
sures of healthcare resource utilization among inpatients
[7]. Given that both the rate of PAR and the LOS can be
effectively reduced by various preventive but often com-
plex and costly interventions, it is essential to identify
patients at higher risk for PAR or prolonged LOS, in
order to improve allocation of these interventions [8–
10]. While previous studies conducted mainly in the
United States, but also Australia, Ireland and Spain,
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described an association between multimorbidity and re-
admission or prolonged LOS [11–18], data in Switzerland
are scarce, with only two studies showing a prolonged
LOS in patients with multimorbidity [1–3]. Nevertheless,
we lack descriptive and more detailed quantitative data on
the association between particular combinations of
chronic comorbidities and PAR or prolonged LOS. Fur-
thermore, more complex effects of chronic comorbidities
on the odds for PAR or prolonged LOS, such as interac-
tions that may lead to more than multiplicative effects on
this odds, have not yet been studied.
Our primary aim was to identify combinations of
chronic comorbidities associated with higher healthcare
resource utilization, measured as PAR and prolonged
LOS, to quantify this association, and to identify poten-
tial interactions between those comorbidities on the
odds for PAR or prolonged LOS. Our hypothesis was
that particular combinations of comorbidities are associ-
ated with a higher odds for PAR or prolonged LOS, and
that some comorbidities found in those combinations
may have a more or a less than multiplicative effect on
this odds. Our secondary aim was to quantify the associ-
ation between the number of chronic diseases and
healthcare resource utilization. Our hypothesis was that
a higher number of chronic diseases is associated with
higher odds for PAR and prolonged LOS.
Methods
Study design, setting, and participants
We used a retrospective cohort including all consecutive
patients with multimorbidity – defined by its most usual
definition, i.e. the presence of at least two chronic dis-
eases [3, 19] – who were discharged home or to a nurs-
ing home from the medical departments of three large
university teaching hospitals in Switzerland (Bern Uni-
versity Hospital [Inselspital], Lausanne University Hos-
pital [CHUV], and Geneva University Hospitals [HUG])
between 2010 and 2011. These three hospitals are com-
parable in terms of size, types of patients cared for and
treatment approaches. This is an ancillary study using
only the Swiss sample from a larger multinational cohort
initially developed to study readmission in four countries
(Canada, USA, Switzerland, Israel) [20]. The unit of ana-
lysis was hospital discharge. All data were extracted from
hospital electronic medical records. We did not assess
death events following discharge. As the data were fully
anonymised, an ethical approval was not required ac-
cording to Swissethics. Reporting is in accordance with
the STrengthening the Reporting of OBservational stud-
ies in Epidemiology (STROBE) statement [21].
Classification of diseases
We used the Chronic Condition Indicator, developed by
the Healthcare Cost and Utilization Project, a Federal-
State-Industry partnership sponsored by the Agency for
Healthcare Research and Quality, to differentiate be-
tween chronic and not chronic diseases [22]. According
to this standardised tool, International Classification of
Diseases (ICD) diagnosis codes are classified as chronic
if they meet following criteria: a health condition lasting
at least 12 months and causing limitations on self-care,
independent living and social interactions, and/or result-
ing in the need for ongoing intervention with medical
products, services and special equipment. To focus on
conditions that define multimorbidity, we included only
chronic diseases in our analysis, and thus excluded ICD
codes for acute diseases, risk factors, symptoms, screen-
ing strategies and complications of diseases, as previ-
ously done [23]. We then collapsed all chronic diseases
into a clinically meaningful number of categories using
the Clinical Classification Software, also developed by
the Healthcare Cost and Utilization Project [24], defin-
ing the different chronic comorbidities to be analysed.
We finally grouped together some of those comorbidities
that were expected to be found in combination (details
in Additional file 1).
Study outcomes
Our primary outcome was potentially avoidable readmis-
sion (PAR) to any department of the same hospital within
30 days following hospital discharge. To identify PAR, we
used the SQLape algorithm, which is based on administra-
tive data and ICD codes and was initially developed in
Switzerland to benchmark hospitals [20, 25]. Shortly, this
algorithm classifies a readmission as unavoidable if it was
predictable, for example for planed chemotherapy or radio-
therapy, or if it involves a new body system not affected
during index admission. Readmissions for transplantation,
severe trauma, severe chronic disease or rehabilitation
treatment are also considered unavoidable. On the other
hand, readmission for complications is deemed avoidable.
Our secondary outcome was a prolonged LOS, assessed
both as a continuous and binary variable. For the binary as-
sessment, we defined a prolonged LOS as a LOS longer or
equal to the upper quartile (75%).
Statistical analyses
We presented patients’ baseline characteristics as me-
dian with interquartile range (IQR) or proportions, as
appropriate.
For the primary aim, we used a mixed-effects logistic
regression adjusted for age and sex, with a random inter-
cept for hospital to identify the 20 combinations of co-
morbidities with the highest odds for PAR and for a
prolonged LOS. For clinical relevance, we only consid-
ered combinations with a prevalence of ≥0.5%. We pre-
sented the results as odds ratio (OR) with 95%
confidence interval (CI). We compared the patients with,
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to the patients without the combinations of comorbidi-
ties. For each of these 20 combinations, we then ana-
lysed interactions to identify the comorbidities that had
a more or a less than multiplicative effect on the odds
for PAR or prolonged LOS. A more than multiplicative
effect means that the OR of the combination is higher
than the ORs of the single comorbidities multiplied to-
gether. A less than multiplicative effect means the op-
posite. We used quantile regression controlled for age,
sex and hospital to assess the difference in median LOS
between patients with and without a combination of
comorbidities.
For the secondary aim, we used a mixed-effects logistic
univariable regression with a random intercept for
centre to quantify the association between the number
of chronic diseases and PAR or prolonged LOS, respect-
ively. We used a forest plot to present the results.
We performed all analyses with STATA 15.1 (Stata-
Corp LP, College Station, TX, USA) or R version 3.4.4
(R Project for Statistical Computing).
Results
Among the 42,739 patients available in the initial co-
hort, 33,871 (79.3%) were multimorbid and included
in the study (Fig. 1). Among them, 1948 (5.8%) had a
PAR within 30 days after discharge, and 9634 (28.4%)
had a prolonged LOS. Median age was 68 years (IQR
56–78), median number of chronic diseases was 4
(IQR 3–6), and median LOS was 8 days (IQR 4–14;
Table 1). Median LOS was 5 days (IQR 2–8) in pa-
tients without prolonged LOS and 18 days (IQR 15–
25) in those with prolonged LOS. The most frequent
comorbidities were chronic heart disease, chronic kid-
ney disease (CKD), solid malignancy and substance-
related disorders, each occurring in more than 10% of
the patients.
Combinations of comorbidities and 30-day potentially
avoidable readmission
Among the 20 combinations of comorbidities with the
highest OR for PAR, 10 included CKD and 7 included
solid malignancy (Table 2). Acute and unspecified renal
failure combined with solid malignancy showed the
highest OR for PAR (OR 2.69, 95%CI 1.81;3.99),
followed by pulmonary heart disease combined with
Fig. 1 Study flow-chart. Abbreviations: PAR, potentially avoidable readmission
Table 1 Baseline characteristics
Characteristics Multimorbid population
(n = 33,871)
Age, years, median (IQR) 68 (56–78)
Men, n (%) 19,170 (56.6)
Length of stay, days, median (IQR) 8 (4–14)
Potentially avoidable readmission, n (%) 1948 (5.8)
Number of admissions in the past year,
median (IQR)
0 (0–2)
Description of multimorbidity
Number of acute and chronic diseases,
median (IQR)
7 (5–10)
Number of chronic diseases, median (IQR) 4 (3–6)
Deyo-Charlson Comorbidity Index,
median (IQR)a
2 (1–3)
Elixhauser-Van Walraven Comorbidity
Index, median (IQR)b
7 (2–12)
Most frequent comorbidities (prevalence > 10%)
Chronic heart disease, n (%) 15,717 (46.4)
Chronic kidney disease, n (%) 5174 (15.3)
Solid malignancy, n (%) 4964 (14,7)
Substance-related disorders, n (%) 4153 (12.3)
Abbreviations: IQR interquartile range, n number
aA prolonged length of stay was defined as a stay longer than or equal to
upper quartile (75%)
aDeyo-Charlson Comorbidity Index ranges from 0 to + 33
bElixhauser-Van Walraven Comorbidity Index ranges from − 19 to + 86
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solid malignancy (OR 2.48, 95% CI 1.70;3.63, Table 2).
The 18 following combinations increased the odds for
PAR by 92 to 140%. CKD in combination with other dis-
eases of kidney and ureters, and CKD in combination
with solid malignancy had a less than multiplicative ef-
fect on the odds for PAR. Paralysis in combination with
other nervous system disorders had a more than multi-
plicative effect on the odds for PAR, while the comor-
bidities of the other 17 combinations showed no
significant interaction (Table 2).
Combinations of comorbidities and prolonged length of
stay
Two combinations of comorbidities showed a particular
high OR for a prolonged LOS and a particular high differ-
ence in median LOS (Table 3): 1) miscellaneous mental
health disorders combined with mood disorders (OR for
prolonged LOS: 11.28, 95%CI 8.71;14.61; difference in me-
dian LOS: 17.4 days, 95%CI 16.5;18.3); 2) diseases of white
blood cells combined with hematological malignancy (OR
for prolonged LOS: 10.95, 95%CI 9.06;13.24; difference in
median LOS: 15.7 days, 95%CI 15.1;16.4).
The 18 following combinations increased the odds for
a prolonged LOS by 179 to 383% and showed a differ-
ence in median LOS of 4 to 8 days. These combinations
included mostly mental health conditions, neurological
diseases and renal diseases. The comorbidities of five
combinations had a more than multiplicative effect on
the odds for a prolonged LOS, while those of three com-
binations had a less than multiplicative effect on this
odds (Table 3).
Number of chronic diseases and healthcare resource
utilization
The odds for PAR increased with each additional
chronic disease, reaching an OR of 2.31 (95%CI 1.87;
2.85) for patients with 10 or more chronic diseases
(Fig. 2). The effect on prolonged LOS was more pro-
nounced, reaching an OR of 9.62 (95% CI 8.51;10.88) in
patients with 10 or more chronic diseases (Fig. 3).
Discussion
In this large sample of medical patients hospitalised in
Switzerland, we identified combinations of chronic co-
morbidities associated with higher healthcare resource
Table 2 Combinations of comorbidities and 30-day potentially avoidable readmission
Combinations of comorbidities a OR (95% CI) Interaction b
Acute and unspecified renal failure Solid malignancy 2.69 (1.81;3.99) 0
Pulmonary heart disease Solid malignancy 2.48 (1.70;3.63) 0
Chronic kidney disease Liver disease 2.40 (1.60;3.60) –
Chronic kidney disease Solid malignancy 2.39 (1.79;3.20) 0
Solid malignancy Chronic obstructive pulmonary disease and bronchiectasis 2.36 (1.75;3.17) 0
Chronic kidney disease Chronic obstructive pulmonary disease and bronchiectasis 2.29 (1.76;2.97) 0
Chronic kidney disease Other nutritional, endocrine or metabolic disorders 2.23 (1.41;3.54) 0
Chronic kidney disease Pulmonary heart disease 2.15 (1.64;2.83) 0
Esophageal disorders Solid malignancy 2.15 (1.39; 3.33) 0
Liver disease Solid malignancy 2.13 (1.41; 3.22) 0
Chronic kidney disease Other and ill-defined heart disease 2.13 (1.45;3.13) 0
Chronic kidney disease Other diseases of kidney and ureters 2.11 (1.41;3.16) –
Chronic kidney disease Thyroid disorders 2.09 (1.53;2.85) 0
Pulmonary heart disease Chronic obstructive pulmonary disease and bronchiectasis 2.06 (1.51;2.80) 0
Chronic kidney disease Chronic heart disease 2.02 (1.77;2.30) 0
Chronic heart disease Systemic lupus erythematosus and connective tissue disorders 2.01 (1.26;3.21) 0
Paralysis Other nervous system disorders 1.98 (1.39;2.82) +
Chronic kidney disease Nephritis, nephrosis, renal sclerosis 1.95 (1.55;2.47) 0
Epilepsy; convulsions Solid malignancy 1.92 (1.25;2.95) 0
Chronic heart disease Other lower respiratory disease 1.92 (1.18;3.13) 0
Abbreviations: CI confidence interval, OR odds ratio, PAR potentially avoidable readmission
a20 combinations with the highest OR for PAR
b The sign "+"represents a significant more than multiplicative effect of the comorbidities found in the combination on the odds for PAR. A more than
multiplicative effect means that the OR of the combination is larger than the ORs of the single comorbidities multiplied together. The sign "-"represents a
significant less than multiplicative effect of the comorbidities found in the combination on the odds for PAR. A less than multiplicative effect means that the OR
of the combination is smaller than the ORs of the single comorbidities multiplied together. The sign "0"means that there is no significant interaction
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utilization, measured as PAR and prolonged LOS. Among
the 20 combinations of comorbidities with the highest
odds for PAR, 10 included CKD. These combinations
increased the odds for PAR by 92 to 169%. Miscellaneous
mental health disorders combined with mood disorders,
and diseases of white blood cells combined with
hematological malignancy, were strongly associated with a
prolonged LOS. The comorbidities of 5 of the 20 combi-
nations with the highest odds for a prolonged LOS had a
more than multiplicative effect on the odds. The number
of chronic diseases was strongly associated with LOS. This
quantitative description of combinations of chronic co-
morbidities with the highest impact on healthcare re-
source utilization may help to identify patients most likely
to benefit from preventive interventions in Switzerland.
Combinations of comorbidities and 30-day potentially
avoidable readmission
CKD was often found among the combinations of co-
morbidities with the highest odds for PAR. Previous
studies described an increased risk for readmission
among patients with CKD, but little was known on
which patients with CKD may be more vulnerable [26–
29]. Our study identified 10 different chronic comorbidi-
ties that increased the odds for PAR when combined
with CKD, with the highest odds for the combinations
including liver disease, solid malignancy and chronic ob-
structive pulmonary disease and bronchiectasis. Paying
particular attention to those comorbidities in patients
with CKD, particularly when developing preventive in-
terventions, may help to reduce the rate of PAR in this
population.
Solid malignancy was also frequently found among
these top combinations. As we included only PAR, we
did not consider patients readmitted for planned chemo-
therapy or radiotherapy in the outcome. Therefore, our
findings suggest that these readmissions were rather re-
lated to complications of treatment or frailty, which is
frequent among those patients and associated with ad-
verse health outcome such as readmission [30–32]. This
report is important, as both frailty and complications of
treatment could be targeted by preventive interventions.
Table 3 Combinations of comorbidities and prolonged length of stay
Combinations of comorbidities a OR (95% CI) b Interaction c Difference in median LOS (95% CI) d
Miscellaneous mental health disorders Mood disorders 11.28 (8.71;14.61) + 17.3 (16.5;18.3)
Diseases of white blood cells Hematological malignancy 10.95 (9.06;13.24) + 15.7 (15.1;16.8)
Chronic heart disease Chronic ulcer of skin 4.83 (3.77;6.17) + 7.8 (6.8;8.7)
Anxiety disorders Mood disorders 4.10 (3.06;5.49) 0 7.6 (6.4;8.8)
Chronic heart disease Diseases of white blood cells 3.92 (3.01;5.11) 0 8.0 (7.0;9.1)
Paralysis Solid malignancy 3.37 (2.54;4.47) 0 6.6 (5.5;7.8)
Chronic heart disease Liver disease 3.36 (2.76;4.08) + 6.2 (5.5;7.0)
Chronic kidney disease Chronic ulcer of skin 3.22 (2.40;4.31) – 5.4 (4.2;6.5)
Chronic heart disease Hematological malignancy 3.21 (2.62;3.92) 0 5.2 (4.3;6.0)
Chronic kidney disease Hematological malignancy 3.16 (2.42;4.14) 0 4.3 (3.2;5.4)
Arthropathy and arthritis Mood disorders 3.10 (2.42;9.96) – 5.7 (4.8;6.7)
Paralysis Other nervous system disorders 3.02 (2.40;3.78) 0 5.1 (4.2;6.0)
Miscellaneous mental health disorders Chronic heart disease 3.01 (2.30;3.93) 0 4.8 (3.8;5.9)
Dementia Mood disorders 2.95 (2.27;3;82) – 5.6 (4.6;6.6)
Paralysis Epilepsy; convulsions 2.92 (2.28;3.75) 0 5.0 (4.0;6.0)
Other nervous system disorders Mood disorders 2.89 (2.28;3.66) 0 5.9 (5.0;6.9)
Chronic kidney disease Liver disease 2.89 (2.19;3.80) 0 4.9 (3.8;6.1)
Dementia Substance-related disorders 2.83 (2.13;3.75) 0 5.1 (3.9;6.2)
Other nervous system disorders Cerebrovascular disease 2.79 (2.21;3.54) 0 4.6 (3.7;5.6)
Epilepsy; convulsions Cerebrovascular disease 2.79 (2.09;3.73) + 5.3 (4.2;6.5)
Abbreviations: CI confidence interval, LOS length of stay, OR odds ratio
a20 combinations with the highest OR for PAR
bA prolonged length of stay was defined as a stay longer than or equal to the upper quartile (75%)
cThe signs "+" and "-"represent a significant more than multiplicative effect and less than multiplicative effect, respectively, of the comorbidities found in the
combination on the odds for a prolonged LOS. A more than multiplicative effect means that the OR of the combination is higher than the ORs of the single
comorbidities multiplied together. The sign "0"means that there is no significant interaction
dp-value < 0.001 for all. A confidence interval not overlapping the zero line means that the difference in median is significant
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Combinations of comorbidities and length of stay
Mood disorders were often found among one fourth of
the combinations of comorbidities with the highest odds
for prolonged LOS, and had the highest impact on the
LOS in combination with miscellaneous mental health
disorders. Previous studies associated psychological or
psychiatric comorbidity with prolonged LOS in general
hospital settings [33, 34]. In our study, we further found
that a combination of psychological or psychiatric co-
morbidities was particularly strongly associated with
prolonged LOS. Additionally, the two comorbidities had
a multiplicative effect on the odds for a prolonged LOS.
As miscellaneous mental health disorders include mostly
sleep disorders not related to a somatic condition, our
finding underlines the importance of paying attention to
minimize factors associated with sleep disturbance dur-
ing hospital stay, and particularly in patients with a pre-
existing psychiatric comorbidity, as they seem more
vulnerable.
The second combination with the highest impact on
LOS was diseases of white blood cells with hematological
malignancy. This could be mainly explained by the
neutropenia either resulting from chemotherapy or dir-
ectly related to hematological malignancy [35]. Unfortu-
nately, we may have only little impact on the prolonged
LOS in this case, as neutropenic patients most often have
to stay in an isolated hospital room, and because of the
frequent and hardly avoidable complications of neutro-
penia, including severe mucositis and infections.
Neurological disorders were also frequent among the
top combinations associated with a prolonged LOS. This
finding is important, as different interventions, depend-
ing on the type of neurological disorder, may impact the
LOS. On the one hand, in patients with cerebrovascular
diseases, care by neurohospitalists or in stroke units have
been shown to shorten the LOS [36, 37]. On the other
hand, disability resulting from neurological disorders,
such as paralysis, increases the need for supportive care
after discharge, which may require some time to
organize because of limited available resources. This is
important, considered that a modification in resource al-
location may decrease this adverse impact on the LOS.
Until now, we lacked data on how the different comor-
bidities may interact to influence the LOS. In this study,
Fig. 2 Association between the number of chronic diseases and 30-day potentially avoidable readmission. Legend: Odds ratio (box) with 95%
confidence interval (lines) for 30-day potentially avoidable readmission. The reference category is the presence of 2 chronic diseases, as we
included only patients with multimorbidity. Abbreviations: #, number of chronic diseases; CI, confidence interval; OR, odds ratio
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we found that the comorbidities of one fourth of the
combinations with the highest OR for a prolonged LOS
showed a more than multiplicative effect on the odds.
This suggests that assessing multimorbidity as a count
or a list of diseases only may mask important additional
information on the higher healthcare resource utilization
associated with specific combinations of comorbidities,
and thus not exactly reflect the complex impact of mul-
timorbidity on the LOS in particular.
Number of chronic diseases and healthcare resource
utilization
A prolonged LOS and a higher rate of readmission had
been associated with the number of diseases, but we
lacked quantitative data on this association [4, 15, 17,
18, 38]. Furthermore, little is known on this association
with PAR, rather than with any readmission. Interest-
ingly, the number of chronic diseases was far more
strongly associated with LOS than with PAR, reaching
an OR of 9.62 for prolonged LOS, but of only 2.31 for
PAR in patients with 10 or more chronic diseases. This
suggests that the number of chronic diseases may
increase patients’ level of complexity, which has in turn
been associated with prolonged LOS [39, 40]. The num-
ber of chronic diseases may thus help to identify patients
that may benefit more of interventions aimed at shorten-
ing LOS. On the other hand, the association between the
number of chronic diseases and PAR was less strong.
This suggests that particular types of diseases, rather
than the number of diseases, are associated with an in-
creased odds for PAR. This hypothesis is supported by
previous data finding a stronger association between
PAR and some diseases, such as infection, neoplasm,
heart failure or gastrointestinal and liver disorders [41].
The number of chronic diseases alone may therefore be
less useful to allocate interventions aimed at reducing
PAR.
Limitations and strengths
Our study presents some limitations. First, although
using ICD codes allowed assessing a broad number of
diseases, diagnoses are subject to coding quality that
may lead to underreporting. Second, we assessed diagno-
ses using hospital records only, which may have led to
Fig. 3 Association between the number of chronic diseases and prolonged length of stay. Legend: Odds ratio (box) with 95% confidence interval
(lines) for prolonged length of stay. The reference category is the presence of 2 chronic diseases, as we included only patients with
multimorbidity. A prolonged length of stay was defined as a stay longer than or equal to the upper quartile (75%). Abbreviations: #, number of
chronic diseases; CI, confidence interval; OR, odds ratio
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some biases in morbidity measurement. However, diagno-
ses are not coded with the ICD system in primary care set-
tings in Switzerland, thus not allowing their classification
with the Chronic Condition Indicator and the Clinical
Classification Software. Third, as our study was not de-
signed to assess causal relationships, we can only report
associations. Fourth, our findings may have limited
generalizability to patients hospitalised in primary or sec-
ondary care hospitals that may be less severely ill than
those cared for in tertiary university teaching hospitals.
This study has several strengths also. First, we used a
large and multicentre sample of patients. Second, we
classified the diseases using standardised tools and con-
sidered all ICD-coded diagnoses, unlike most previous
studies that often included a limited number of diseases
[4, 22, 24, 42–45]. Finally, we used innovative methods
to measure multimorbidity and its impacts on healthcare
resource utilization, such as the assessment of combina-
tions of comorbidities and of interactions between the
comorbidities.
Conclusions
In this large multicentre analysis of multimorbid medical
inpatients, we found that half of the combinations of co-
morbidities most strongly associated with PAR included
CKD and one third of them included solid malignancy.
This should prompt physicians and researchers to de-
velop specific preventive interventions particularly fo-
cused on these groups of patients, with the aim to
reduce the risk of PAR and thus the burden of disease
for patients with CKD or solid malignancy. Miscellan-
eous mental health disorders combined with mood dis-
orders, and diseases of white blood cells combined with
hematological malignancy, were the most strongly asso-
ciated with LOS, with a difference in median LOS of
17.4 and 15.7 days, respectively. Hospital physicians car-
ing for medical patients should thus be particularly at-
tentive to identify and take care of mental health
conditions, particularly sleep disorders, as these comor-
bidities may easily go unnoticed, but are associated with
higher healthcare utilization. The number of chronic dis-
eases was far more strongly associated with prolonged
LOS than with PAR. This measure of multimorbidity
may thus be more useful to identify patients at risk of
prolonged LOS that may most benefit of interventions
to shorten LOS.
In conclusion, this detailed and quantitative description
may help healthcare providers to identify patients with
combinations of diseases associated with higher healthcare
resource utilization, and thus to better focus preventive in-
terventions in order to reduce PAR and shorten LOS, with
the overall objective to decrease healthcare costs and ad-
verse consequences of multimorbidity for the patients,
without decreasing quality of care.
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